Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 8, 2006, Pages 2626-2631

  Tam, Vincent H ^a   Kabbara, Samer ^a   Vo, Giao ^a   Schilling, Amy N ^a   Coyle, Elizabeth A ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOLLOW FIBER INFECTION MODEL; IN VITRO STUDY; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS; STRAIN IDENTIFICATION; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENTAMICINS; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 33746919042     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01165-05     Document Type: Article

References (26)

1. Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. Effect of 2′,3′-didchydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agents Chemother. 38:1386-1391.
2. Blaser, J. 1991. Efficacy of once- and thrice-daily dosing of aminoglycosides in in-vitro models of infection. J. Antimicrob. Chemother. 27(Suppl. C):21-28.
3. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
4. Chuck, S. K., S. R. Raber, K. A. Rodvold, and D. Areff. 2000. National survey of extended-interval aminoglycoside dosing. Clin. Infect. Dis. 30:433-439.
5. Craig, W. A., and S. C. Ebert. 1990. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. Suppl. 74:63-70.
6. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
7. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical simulations resource. University of Southern California, Los Angeles.
8. De Broe, M. E., R. A. Giuliano, and G. A. Verpooten. 1986. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am. J. Med. 80:115-118.
9. den Hollander, J. G., K. Fuursted, H. A. Verbrugh, and J. W. Mouton. 1998. Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob. Agents Chemother. 42:749-754.
10. den Hollander, J. G., J. W. Mouton, M. P. van Goor, F. P. Vleggaar, and H. A. Verbrugh. 1996. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinctic model. Antimicrob. Agents Chemother. 40:784-786.
11. Dudley, M. N., and S. H. Zinner. 1991. Single daily dosing of amikacin in an in-vitro model. J. Antimicrob. Chemother. 27(Suppl. C):15-19.
12. Kashuba, A. D., J. S. Bertino, Jr., and A. N. Nafziger. 1998. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob. Agents Chemother. 42:1842-1844.
13. Kashuba, A. D., A. N. Nafziger, G. L. Drusano, and J. S. Bertino, Jr. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob. Agents Chemother. 43:623-629.
14. Lacy, M. K., D. P. Nicolau, C. H. Nightingale, and R. Quintiliani. 1998. The pharmacodynamics of aminoglycosides. Clin. Infect. Dis. 27:23-27.
15. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
16. Mouton, J. W., N. Jacobs, H. Tiddens, and A. M. Horrevorts. 2005. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 52:123-127.
17. Murry, K. R., P. S. McKinnon, B. Mitrzyk, and M. J. Rybak. 1999. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 19:1252-1260.
18. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard. NCCLS, Wayne, Pa.
19. Pereira, M. S., N. C. Leal, T. C. Leal, M. Sobreira, A. M. de Almeida, J. P. Siqueira-Junior, and G. M. Campos-Takaki. 2002. Typing of human and bovine Staphylococcus aureus by RAPD-PCR and ribotyping-PCR. Lett. Appl. Microbiol. 35:32-36.
20. Rybak, M. J., B. J. Abate, S. L. Kang, M. J. Ruffing, S. A. Lerner, and G. L. Drusano. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555.
21. Tam, V. H., S. L. Preston, and L. L. Briceland. 1999. Once-daily aminoglycosides in the treatment of gram-positive endocarditis. Ann. Pharmacother. 33:600-606.
22. Tam, V. H., A. N. Schilling, and M. Nikolaou. 2005. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J. Antimicrob. Chemother. 55:699-706.
23. Tsuji, B. T., and M. J. Rybak. 2005. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49:2735-2745.
24. Tulkens, P. M. 1986. Experimental studies on nephrotoxicity of aminoglycosides at low doses. Mechanisms and perspectives. Am. J. Med. 80:105-114.
25. Turnidge, J. 2003. Pharmacodynamics and dosing of aminoglycosides. Infect. Dis. Clin. N. Am. 17:503-528.
26. Xiong, Y. Q., J. Caillon, M. F. Kergueris, H. Drugeon, D. Baron, G. Potel, and A. S. Bayer. 1997. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob. Agents Chemother. 41:823-826.